| Stephen P Sanders, MD | |
|
22 Bramhall St, Portland, ME 04102-3134 | |
| (207) 662-7060 | |
| Not Available |
| Full Name | Stephen P Sanders |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 20 Years |
| Location | 22 Bramhall St, Portland, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275608556 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD17233 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Memorial Hospital, The | North conway, NH | Hospital |
| Stephens Memorial Hospital | Norway, ME | Hospital |
| Franklin Memorial Hospital | Farmington, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
News Archive
Washington State University scientists have developed a method to detect the biomarkers for Alzheimer's disease that is 10 times more sensitive than current blood testing technology.
In Georgia, some navigator events were canceled after health law opponents held a protest at one and posted other events on its website, urging more protests. In South Dakota, meanwhile, a lawmaker introduced a bill to require state registration and background checks of the insurance guides. And a New Hampshire hospital that was excluded from Anthem's network is in the news because it is challenging that decision.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
The number of smokers who have quit over the last three decades has multiplied as a result of public-health campaigns, but now researchers in the U.S. say people quit smoking as groups and not as individuals.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Washington State University scientists have developed a method to detect the biomarkers for Alzheimer's disease that is 10 times more sensitive than current blood testing technology.
In Georgia, some navigator events were canceled after health law opponents held a protest at one and posted other events on its website, urging more protests. In South Dakota, meanwhile, a lawmaker introduced a bill to require state registration and background checks of the insurance guides. And a New Hampshire hospital that was excluded from Anthem's network is in the news because it is challenging that decision.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
The number of smokers who have quit over the last three decades has multiplied as a result of public-health campaigns, but now researchers in the U.S. say people quit smoking as groups and not as individuals.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| Entity Name | Southern Maine Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659392819 PECOS PAC ID: 0143208348 Enrollment ID: O20040713001060 |
News Archive
Washington State University scientists have developed a method to detect the biomarkers for Alzheimer's disease that is 10 times more sensitive than current blood testing technology.
In Georgia, some navigator events were canceled after health law opponents held a protest at one and posted other events on its website, urging more protests. In South Dakota, meanwhile, a lawmaker introduced a bill to require state registration and background checks of the insurance guides. And a New Hampshire hospital that was excluded from Anthem's network is in the news because it is challenging that decision.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
The number of smokers who have quit over the last three decades has multiplied as a result of public-health campaigns, but now researchers in the U.S. say people quit smoking as groups and not as individuals.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| Entity Name | York Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376528398 PECOS PAC ID: 6406766781 Enrollment ID: O20040812001065 |
News Archive
Washington State University scientists have developed a method to detect the biomarkers for Alzheimer's disease that is 10 times more sensitive than current blood testing technology.
In Georgia, some navigator events were canceled after health law opponents held a protest at one and posted other events on its website, urging more protests. In South Dakota, meanwhile, a lawmaker introduced a bill to require state registration and background checks of the insurance guides. And a New Hampshire hospital that was excluded from Anthem's network is in the news because it is challenging that decision.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
The number of smokers who have quit over the last three decades has multiplied as a result of public-health campaigns, but now researchers in the U.S. say people quit smoking as groups and not as individuals.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen P Sanders, MD 22 Bramhall St, Portland, ME 04102-3134 Ph: (207) 662-7060 | Stephen P Sanders, MD 22 Bramhall St, Portland, ME 04102-3134 Ph: (207) 662-7060 |
News Archive
Washington State University scientists have developed a method to detect the biomarkers for Alzheimer's disease that is 10 times more sensitive than current blood testing technology.
In Georgia, some navigator events were canceled after health law opponents held a protest at one and posted other events on its website, urging more protests. In South Dakota, meanwhile, a lawmaker introduced a bill to require state registration and background checks of the insurance guides. And a New Hampshire hospital that was excluded from Anthem's network is in the news because it is challenging that decision.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
The number of smokers who have quit over the last three decades has multiplied as a result of public-health campaigns, but now researchers in the U.S. say people quit smoking as groups and not as individuals.
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.
› Verified 1 days ago
Thomas M Eslinger, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-7010 Fax: 207-662-7025 | |
Dr. Christopher T Bowe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-7010 Fax: 207-662-7025 | |
Sandra L Stevens, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 | |
Dr. Gregory Scott Heaphy, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Dr. Eric G Lowe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-7060 Fax: 207-662-7066 | |
Caitlin Bonney, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-3281 | |
Christopher James Watson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2381 |